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Abstract: Cisplatin is one of the most effective cytotoxic
agents against cancers. Its usage, however, is limited
because of severe resistance and systemic toxicity. A for-
mulation of cisplatin-loaded Au–Au2S nanoparticles (NPs)
with near-IR (NIR) sensitivity is reported to partly over-
come this limitation in this paper. NIR sensitive Au–Au2S
NPs were successfully synthesized by the reduction of tet-
rachloroauric acid (HAuCl4) using sodium sulfide (Na2S),
and cisplatin was loaded onto Au–Au2S NPs via a MUA
(11-mercaptoundecanoic acid) layer. To further investigate
the biological safety of cisplatin-loaded Au–Au2S NPs,
three different cell lines were used to investigate the acute
cytotoxicity and the long-term potential carcinogenicity
in vitro. Cisplatin-loaded Au–Au2S NPs were also tested
for limited hemocompatibility in vitro. Our in vitro short
and long-term data provided preliminary evidence sug-
gesting that cisplatin-loaded Au–Au2S NPs with NIR sen-
sitivity are nontoxic below the maximum recommended
dosage.  2007 Wiley Periodicals, Inc. J Biomed Mater Res
85A: 787–796, 2008
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INTRODUCTION
Cisplatin [cis-diamminedichloro platinum (II)] is
one of the most widely used and effective cytotoxic
agents in the treatment of malignancy of lung, head,
neck, testes, and ovary.1,2 It is proved that after both
passive and active cellular uptake, cisplatin may
react with the N7 atom of guanine in DNA to form
adducts and causes cellular apoptosis.3 However,
chronic cisplatin usage results in resistance by sev-
eral possible mechanisms including increased inter-
actions with metallothionein and glutathione as well
as increased DNA repair.4 To counteract resistance,
which lowers the efficiency of cisplatin significantly,
very high systemic doses of cisplatin are adminis-
tered. Unfortunately, such high dose of cisplatin
results in severe systemic toxicity and poor patient
compliance, including nausea/vomiting, renal toxic-
ity, gastrointestinal toxicity, peripheral neuropathy,
asthenia, and ototoxicity, thus limiting its clinical
use.5,6 To improve the efficacy and safety of cispla-
tin, a variety of methods are applied to drug deliv-
ery system (DDS), which include particulate carriers,
such as liposomes, polymers, and nanoparticles
(NPs).7–9 The drug carriers may concentrate in the
tumor because tumors exhibit a unique enhanced
permeability and retention effect for 50–100 nm par-
ticles. As a result of this, a large increase in tumor
drug concentrations (10-fold or higher) could be
achieved relative to administration of the same dose
of free drug,10 thereby decreasing the massive
systemic side effects of conventional chemotherapy.
On the other hand, the interaction of laser energy
with different absorbing NPs, such as carbon nano-
tubes, metal nanospheres, nanoshells, or others, is a
rapidly expanding area in the treatment of cancer.11,12
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The combination of light and photosensitizers induce
selective death of tumor cells while leaving normal
tissues intact. In particular, near-IR (NIR) light is very
useful in treating tumors, because of its deep trans-
mission into body tissues without significant tissue
damage.13,14 From this point of view, photothermal
therapy using NIR absorbers has been investigated.
For example, West and coworkers reported photo-
thermal ablation of tumor tissues using silica–gold
nanoshells.15 The accumulated heat due to absorption
of continuous NIR laser radiation resulted in site-
specific selective cell destruction.
Following literatures,16,17 we have successfully syn-
thesized Au–Au2S NPs with NIR sensitivity. These
as-synthesized Au–Au2S NPs were chemically stable
and exhibited two absorption bands at 520 nm and in
the NIR region of 650–1100 nm.18 Cisplatin was also
loaded onto Au–Au2S NPs through an 11-mercap-
toundecanoic acid (MUA) layer to develop a targeted
DDS by using tissue penetrative NIR light to trigger
drug release. Those cisplatin-loaded Au–Au2S NPs
were stable in physiological conditions where pH is
about 7.2–7.4; however, when NIR light is applied in
therapy, *90% cisplatin could be released from the
NPs. Therefore, Au–Au2S NPs showed a great prom-
ise as drug delivery carriers because of the unusual
characteristics of NIR sensitivity.
It is evident that, for any clinical application, bio-
compatibility of the materials is crucial. However, to
our knowledge, little attention has been focused on
the biocompatibility of NIR sensitive Au–Au2S NPs.
Another issue that requires to be tackled prior to seri-
ous biomedical application of Au–Au2S NPs is that of
the mode of internalization of the NPs in the cells and
their subsequent localization. The present study was
thus undertaken to further investigate the cellular
uptake, acute cytotoxicity, and the long-term potential
carcinogenicity in vitro of cisplatin-loaded Au–Au2S
NPs with NIR sensitivity for potential cancer therapy.
MATERIALS AND METHODS
Materials
Chloroauric acid (HAuCl4  4H2O) was obtained from
Acros Organics (Belgium). Sodium sulfide (Na2S  9H2O),
11-mercaptoundecanoic acid (MUA, HS(CH2)10COOH), cis-
platin (cis-[Pt(NH3)2Cl2]), dimethylsulfoxide (DMSO), 3-
(4,5-dimethylthiazol-z-yl)-2,5-dipheny-tetrazotium bromide
(MTT), and ITES (contains 1.0 mg/mL insulin from bovine
pancreas, 0.55 mg/mL human transferrin, and 0.5 lg/mL
sodium selenite) were obtained from Sigma (USA). 3-
Methylcholanthrene (MCA) was purchased from Supelco
(USA). 12-O-Tetradecanoylphorbol-13-acetate (TPA) was
from Calbiochem (Germany). Dulbecco’s modified Eagle’s
medium (DMEM), Dulbecco’s modified Eagle’s medium
nutrient mixture /F-12 Ham’s (DMEM/F12), penicillin,
streptomycin, and fetal bovine serum (FBS) were pur-
chased from Hyclone (New Zealand). The other solvents
and reagents were of analytical grade and used without
further purification. The glassware were thoroughly
cleaned and rinsed with deionized water.
Synthesis
The growth of Au–Au2S NPs occurred when the aqueous
solutions of HAuCl4 and Na2S were mixed.
16–18 In principle,
20 mL of 2 mM HAuCl4 was mixed with 20 mL of 1 mM
Na2S, and stored at 258C for 1 day. The reaction was moni-
tored using a UV–visible spectrophotometer at a range of
400–1100 nm. After centrifuging at 15,000 rpm, Au–Au2S
NPs were re-dispersed in a 100 mM MUA solution in etha-
nol for 3 days at 408C. Excess MUA was removed from
solution by at least three repeated cycles of centrifuging at
15,000 rpm, and subsequently re-dispersed in water. Finally,
10 mg of cisplatin was mixed with 10 mL MUA-modified
Au–Au2S NPs by sonication. Afterwards, the flask contain-
ing the drug carriers was capped and left to stand for 2 days.
Cisplatin-loaded Au–Au2S NPs were washed at least three
times and dispersed in water. Determination of the loading
degree of cisplatin on Au–Au2S NPs was carried out by high
performance liquid chromatography (HPLC) method.18 The
morphological examination of the as-synthesized NPs was
performed by transmission electron microscope (JEOL 3010)
equipped with a LaB6 gun operated at an accelerating volt-
age of 300 kV. Zeta potential of NPs dispersed in 0.1M PBS
buffer at pH ¼ 7.0 were determined by Zetasizer 2000 Laser
particle analyzer (Malvern Instruments, UK). Five replicates
were measured and the results were averaged.
Cell culture
Mouse embryonic fibroblast (NIH/3T3) cells, Chinese
hamster lung fibroblast (CHL) cells, and primary mouse
embryo fibroblasts (PMEF) cells were used in the following
experiments. All cells were grown in tissue culture plates
(corning, USA) at 378C in a humidified incubator with 5%
CO2. Cells were cultured in DMEM, supplemented with
10% FBS, and 1% penicillin and streptomycin. PMEF cells
were isolated in our laboratory according to the protocol
developed by Freshney.19 Briefly, the mouse embryos at day
13 of gestation were collected after killing the mouse accord-
ing to institutional guidelines. After the head, internal
organs and limbs of the obtained embryos were pinched off,
the remainder was rinsed three times with PBS, and then cut
into 1 mm 3 1 mm 3 1 mm of pieces in the presence of
0.25% trypsin for 20 min in a sterile dish at 378C. Trypsin
was inactivated by addition of DMEM containing 10% FBS
and 1% penicillin and streptomycin. The cells were used for
the cytotoxicity experiments between passages 2 and 3.
Cellular uptake analysis
Au–Au2S NPs were filtered by 0.22 lm membrane to be
sterilized before use. To study cellular uptake of NPs,
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CHL cells were cultured in 60 mm plates with DMEM for
20 h, after which Au–Au2S NPs or cisplatin-loaded Au–
Au2S NPs were added to the cell culture media at a con-
centration of 0.4 mg/mL. After co-culture for 6 h, the cells
were scraped, washed thoroughly with chilled PBS, pel-
leted by centrifugation, and fixed with 2.5% glutaralde-
hyde. The cell pellets were then postfixed and stained with
1% osmium tetraoxide in 0.1M PBS, and subsequently
dehydrated in an alcohol series, embedded in Epon 618,
and sliced to a thickness of 50–70 nm. Images of the slices
were taken with a transmission electron microscope (JEOL,
JEM-2100) at 120 kV.
For quantification of the intracellular uptake of the NPs,
both of media and cells were respectively collected and
digested by a microwave accelerated reaction system
(CEM MARS 240/50), following the preset protocols. The
amount of Au in cells and media were respectively quanti-
fied using an inductively coupled plasma mass spectrome-
try (ICP-MS, Perkin Elmer SCIEX ELAN DRC-e). Ten parts
per billion Au aqueous solution (purchased from National
Research Center for CRM’S) was used as the standard con-
trol. Five replicates were measured and the results were
averaged.
MTT assay
The cytotoxicity induced by Au–Au2S NPs was deter-
mined by the MTT reduction experiment. Hela, NIH3T3,
and PMEF cells were respectively seeded in 96-well plates
at a density of 1 3 104 cells per well in 100 lL media. The
medium was then removed and replaced with fresh me-
dium containing Au–Au2S NPs or cisplatin-loaded Au–
Au2S NPs at various concentrations ranging from 0.5 to
650 lg/mL (100 lL/well). Cells treated with medium only
served as a negative control group. Incubations were made
for 24 h and 72 h before removal of media containing NPs.
20 lL MTT (5 mg/mL in PBS) was added to each well and
then the plate was further incubated for 4 h under normal
growing conditions. At the end of the assay, each medium
was removed and 100 lL DMSO was added to dissolve
the blue formazan crystal by proliferating cells. Absorb-
ance was measured at 490 nm by using a spectrophotomet-
ric microplate reader (Bio-tek ELX800), and the cell viabil-
ity was expressed as a percentage relative to untreated
control cells. All experiments were performed three times
in triplicate. The concentration that inhibited cell growth
by 50% (IC50) was determined from the dose–response
curve.
Two-stage cell transformation assay
Carcinogenic process could be modeled in vitro on the
basis of morphological cell transformation.20,21 Transforma-
tion assay using NIH3T3 cells could simulate the process
of two-stage carcinogenesis, initiation, and promotion. The
cells are treated at different growth states and therefore
potentially detect not only initiating activity, but also pro-
moting activity of materials.20 In this work, two-stage cell
transformation assay was performed according to the rec-
ommended protocol.22–24 In the initiation assay, NIH3T3
cells were seeded for each treatment at a density of 1.2 3
104/dish in 10 replicates per treatment. After incubation
for 24 h, Au–Au2S NPs or cisplatin-loaded Au–Au2S NPs
as the initiator, 2% DMSO (negative control), and 0.2 lg/
mL MCA (positive control) were added, respectively. After
treatment for 72 h, DMEM was replaced with fresh
DMEM: HAM’S F-12 supplemented with 1% ITES and 2%
FBS. On the 7th day after the beginning of treatment,
0.1 lg/mL TPA (promoter) or 2% DMSO (negative control)
was added to the cultures as the first promoter treatment.
For the second and third promoter treatments, TPA or
DMSO was added on the 11th and 14th day, respectively.
In the promotion assay, 0.2 lg/mL MCA (initiator) or 2%
DMSO (negative control) was added after seeding cells for
24 h. On the 4th day, DMEM was replaced with fresh
DMEM: HAM’S F-12 supplemented with 1% ITES and 2%
FBS. On the 7th day, 2% DMSO (negative control), NPs at
various concentration (promoter), or 0.1 lg/mL TPA (posi-
tive control) were added to the culture, respectively. NPs
and TPA were also added on the 11th and 14th day, respec-
tively. The cells were then fixed with methanol and stained
with Giemsa solution on the 25th day for both assays. Scor-
ing of transformed foci was performed according to the fol-
lowing criteria: (1) foci of more than 2 mm in diameter; (2)
deep basophilic staining; (3) piling up of cells forming a
dense multi-layer; and (4) random orientation of cells at the
edge of foci. The average number of foci (foci/dish) for
each dose was compared with the negative control.
Hemolysis assay
Au–Au2S NPs were tested for limited hemocompatibil-
ity in vitro. A hemolysis test was done by modification of
direct contact method.25 In short, blood from healthy New
Zealand rabbits was collected in 0.5 mL heparin sodium
(300 U). Eight milliliters of heparinized blood was then
diluted by 10 mL saline solution. Saline solution and
deionized water were taken as negative (0% hemolysis)
and positive (100% hemolysis) control, respectively. All the
test specimens were placed in water bath at 378C for
30 min. After that, 0.2 mL of heparinized and diluted
blood were added in each tube and mixed softly, and then
placed in the water bath again at 378C for 60 min. After
incubation, all tubes were centrifuged at 2500 rpm for
5 min and the supernatant was taken for the estimation of
the release of hemoglobin. The absorption at 545 nm was
measured by spectrophotometer (Shimadzu DU800). Each
sample was repeated triplicate. The results were calculated
according to the equation following:
Hemolysis ratio (HR%) ¼ ½ðQDNPs QDNCÞ
=ðQDPC QDNCÞ 3 100%
Statistical analysis
Data are summarized as the mean 6 SD (n ¼ 3) for the
indicated number of separate experiments. Statistical anal-
ysis of data was performed with one-way analysis of var-
iance (ANOVA) followed by a t-test. p-values less than
0.05 were considered significant.
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RESULTS AND DISCUSSION
Characterization
The NIR-sensitive Au–Au2S NPs employed for the
drug delivery carriers in our work were synthesized
by reduction of tetrachloroauric acid (HAuCl4) using
sodium sulfide (Na2S), following earlier methods.
16–18
From counting *110 particles, typical size distribu-
tion of the polygonal particles was estimated to be
*50 nm [Fig. 1(a)]. These as-synthesized Au–Au2S
NPs exhibited two absorption bands as illustrated in
Figure 1(b). The band I at 520 nm was assigned to
the surface plasmon resonance of the Au NPs,
whereas the band II at 760 nm (NIR region) was
attributed to multiply twinned Au-rich particles con-
taining S.26 We also loaded 30 mg cisplatin onto per
mg Au–Au2S NPs via a MUA layer, and the spectro-
photometric analysis revealed that there was only
<10% reduction for NIR absorbing ability after load-
ing with cisplatin.18 Moreover, cisplatin-loaded Au–
Au2S NPs had a higher surface charge (*20 mV)
than the bare Au–Au2S NPs (*7 mV). These data
are in agreement with our previous findings.18,26
Cellular uptake
Since the cellular uptake efficiency of cisplatin-
loaded Au–Au2S NPs may affect the therapeutic
effects, an understanding of the uptake of Au–Au2S
NPs is extremely important. The presence of the
Au–Au2S NPs in CHL cells was confirmed by TEM
and ICP-MS, respectively. ICP-MS results indicated
that (18.4 6 0.4)% Au–Au2S NPs and (19.7 6 0.8)%
cisplatin-loaded Au–Au2S NPs were taken up by the
cells after co-culture for 6 h, respectively. The mor-
phology and position of the Au–Au2S NPs with
respect to cellular ultrastructure were also monitored
by TEM. Untreated cells were taken as the control
(data not shown here). Figure 2 shows the typical
TEM images of the ultrastructural features of CHL
cells exposed to Au–Au2S NPs, which could be
clearly observed as high contrast particle aggregates.
The presence of the intact cellular membranes
strongly suggested that the cell was viable and meta-
bolically active. Both individual and aggregated of
NPs could be observed associated with the plasma
membrane or in small vesicles, some of which were
close to, but not in the, mitochondria or nucleus. The
TEM image of Au–Au2S NPs was similar to cispla-
tin-loaded Au–Au2S NPs (data not shown here); the
only difference is that within the vesicles, the Au–
Au2S NPs appeared to be dispersed, whereas cispla-
tin-loaded Au–Au2S NPs tended to aggregate. Fig-
ure 2(a) verifies that Au–Au2S NPs was internalized
into the cells through an endocytotic process. During
the process of endocytosis, a part of the cellular mem-
brane underwent invagination, thereby enclosing Au–
Au2S NPs into endosomes. These endosomes are
known to undergo a maturation process to form lyso-
somes and trafficked to various cellular compart-
ments.27 Interestingly, a lysosome containing Au–
Au2S NPs lying immediately outside the nuclear
membrane could be seen in Figure 2(b). Suh et al.
attributed this directed intracellular movement of
nanocarriers as an active transport process driven by
molecular motor proteins.28 TEM analysis thus pro-
vided compelling evidence for cellular uptake of Au–
Au2S NPs, their internalization in lysosomes, and
movement of these lysosomal bodies toward the nu-
cleus; but Au–Au2S NPs did not enter the nucleus.
Cytotoxicity
MTT assay is based on the mitochondrial dehydro-
genase activities.29 It is considered an easy and rapid
test for the evaluation of cytotoxicity and was used
Figure 1. (a) Transmission electron microscopy image, and
(b) UV–vis spectrum of the as-synthesized Au–Au2S NPs.
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in this work to assess the cytotoxicity of the as-syn-
thesized Au–Au2S NPs. We tested three cellular
models: CHL, NIH/3T3, and PMEF cells, respec-
tively. Since NIH/3T3 and CHL cells exhibited simi-
lar data, the CHL and PMEF cells were chosen in
the following elucidation. Figure 3 showed the dos-
age response curves of CHL and PMEF cells, which
were treated with Au–Au2S NPs and cisplatin-
loaded Au–Au2S NPs for 24 h and 72 h, respectively.
After incubation with those NPs for 24 h, both cells
showed no significant effect on mitochondrial activ-
ity at concentrations below 100 lg/mL, which could
be considered as nontoxic. Analysis of the data in
Figure 3 demonstrated that although both NPs
afforded a concentration-dependent decrease in the
cell viability, the calculated values of IC50 were dif-
ferent. Namely, as exposure for 24 h, the IC50 values
of Au–Au2S NPs in CHL and PMEF cells were 500
and 400 lg/mL, respectively; in cisplatin-loaded
Au–Au2S NPs group, the IC50 were 200 and 150 lg/
mL in CHL and PMEF cells, respectively. In compar-
ison, the cytotoxic effects of exposure for 72 h were
much stronger with a significant inhibition of mito-
chondrial function in all concentrations than that for
24 h. When reaching to 72 h, the IC50 values of Au–
Au2S NPs in CHL and PMEF cells were 160 and
50 lg/mL, respectively; in cisplatin-loaded Au–Au2S
NPs group, the IC50 were 50 and 15 lg/mL in CHL
and PMEF, respectively. Thus, both of Au–Au2S NPs
and cisplatin-loaded Au–Au2S NPs may cause both
dose- and time-dependent cytotoxicity, this is con-
sistent with earlier literature for other NPs.30–32
To evaluate the effects of the loaded cisplatin on
cells viability, the normalized cisplatin-loaded Au–
Au2S NPs were compared with Au–Au2S NPs, as
shown in Figure 4. The results demonstrated that the
cell viability of cisplatin-loaded Au–Au2S NPs
decreased more significantly than the bare Au–Au2S
Figure 2. Transmission electron microscopy images of
Au–Au2S NPs internalized within the CHL cells. Au–Au2S
NPs were shown as high contrast particle aggregates.
Figure 3. Survival curves for (a) CHL cells and (b) PMEF
cells exposed to Au–Au2S NPs (NPs) and cisplatin-loaded
Au–Au2S NPs (Pt-NPs) for 24 h and 72 h, respectively. Bars
represent the corresponding standard deviations (n ¼ 3).
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NPs. However, it should be noted that *30 mg cis-
platin was loaded onto per mg Au–Au2S NPs. If tak-
ing an adult (weight 60 kg, height 170 cm) for exam-
ple, the suggested cisplatin dosage instructed by US
Pharmacopoeia after conversion is 16–38 lg/mL in
blood, which is far less than our tested concentra-
tions of cytotoxicity. Our current results thus indi-
cated that cisplatin-loaded Au–Au2S NPs might be
noncytotoxic below the maximum recommended
dosage.
The mechanism of cytotoxicity caused by Au–
Au2S NPs and cisplatin-loaded Au–Au2S NPs is not
yet fully understood. It seems that there would be
three reasonable explanations for the current obser-
vation. First, it could be expected that intracellular
NP concentration may affect cell viability by interact-
ing with cellular components.30 This may explain the
dose-dependent effects observed with both NPs on
cell viability, because our ICP-MS results indicated
that *19% NPs were uptaken by cells for each
tested dose. Second, the intracellular NPs are likely
to have an effect on cellular function (DNA replica-
tion, cell division, and so on), resulting in less cell
viability when compared to untreated cells.30,31
Hence, the reason of the time-dependent cytotoxic
effects could be that the cellular damage was
enlarged with longer retention time of intracellular
NPs. Third, another possibility could be the effec-
tiveness of the released cisplatin (*1.2%),18 which
could increase more disruption of cellular compo-
nents, thereby cisplatin-loaded Au–Au2S NPs exhib-
iting a higher cytotoxicity than the bare Au–Au2S
NPs. However, whether cytotoxic effects are mainly
mediated by interactions of NPs with cell mem-
branes or by cellular uptake and subsequent activa-
tion of intracellular signal transduction pathways
remains controversial. The apoptotic or necrotic na-
ture of the NPs’ cytotoxicity also should be taken
into account in the further work.
In vitro carcinogenicity
Biocompatibility as well as functional benefits and
efficacy in meeting clinical objectives are essential
characteristics for biomaterials designed to enhance
biological safety in use. It is well known that noncy-
totoxic chemicals may sometimes induce carcinogen-
esis. Therefore, we evaluated the tumor-promoting
activity of the extracts using the two-stage cell trans-
formation assay, because this in vitro assay is recom-
mended as a useful tool to assess the carcinogenic
potential of chemical since it shows a good correla-
tion (69–85%) with the in vivo long-term carcinogenic
bioassays.33 In the present study, a medium-term
(25 days) in vitro NIH/3T3 cell transformation test
was performed to explore the cellular interaction
with the Au–Au2S NPs, and to reveal possible long-
term effects of this new DDS on cellular behavior.
Table I shows the results of initiating activity in
the two-stage transformation assay using NIH/3T3
cells. The concentration that induced growth inhibi-
tion above 50% compared with the control culture
was chosen as the highest concentration of each
specimen for use in the transformation assay. At ini-
tiating stage, the corresponding IC50 values of Au–
Au2S NPs and cisplatin-loaded NPs were 220 and
100 lg/mL, respectively. At promoting stage, they
were 200 and 90 lg/mL for Au–Au2S NPs and cis-
platin-loaded NPs, respectively. When using 300 and
30 lg/mL Au–Au2S NPs as initiators, without TPA
post-treatment, the mean number of transformed
foci per dish was 0.80 and 0.40; while with TPA
post-treatment, it reached 1.00 and 0.60, respectively.
In the case of cisplatin-loaded Au–Au2S NPs at 125
and 12.5 lg/mL, without and with TPA treatment at
the promotion stage, the mean number of trans-
formed foci per dish was 0.70 and 0.50, 0.90 and 0.60
respectively. Obviously, the mean number of foci/
dish slightly increased when TPA was added at the
promotion stage. However, no significant difference
between each specimen and negative control was
observed, while a statistically significant increase
was observed for the positive control group com-
pared with the negative. The results obtained in the
transformation promoting activity were reported in
Table II. At 200 as well as 20 lg/mL doses of Au–
Au2S NPs, without MCA pretreatment, the mean
number of transformed foci per dish was 0.70 and
Figure 4. Normalized dose–response for cell viability of
Au–Au2S NPs (NPs) and cisplatin-loaded Au–Au2S NPs
(Pt-NPs). CHL cells and PMEF cells were continuously
exposed to NPs for 72 h, respectively. Bars represent the
corresponding standard deviations (n ¼ 3), and * denotes
the significant difference (p < 0.05) for each independent
comparison.
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0.50; with MCA pre-treatment, it reached 1.10 and
0.60, respectively. When cisplatin-loaded Au–Au2S
NPs was used as promoter at 80 and 8 lg/mL, with-
out MCA pretreatment, the mean number of trans-
formed foci per dish was 0.80 and 0.60; with MCA
pretreatment, it reached 1.50 and 0.80, respectively.
Comparing with MCA pretreated or not, in pretreat-
ment group the number of foci was generally
increased, but no statistically significant difference
was observed compared with the negative control
group. Foci/dish number of comparison between
Au–Au2S NPs and cisplatin-loaded Au–Au2S NPs
indicated that cisplatin-loaded Au–Au2S NPs had
twofold transforming activity than Au–Au2S NPs.
Noted that our tested concentrations of carcinogenic-
ity were far more than the suggested dosage
instructed by US pharmacopoeia. Hence, the present
assay showed that both Au–Au2S NPs (<300 lg/
mL) and cisplatin-loaded Au–Au2S NPs (<125 lg/
mL) had no significant tumor-initiating activity as
well as no tumor-promoting activity, thus not caus-
ing carcinogenicity below the maximum recom-
mended dosage.
Light microscopic examination of the cells exposed
to transformation process revealed some morpholog-
ical alterations compared to the normal cells (Image
not shown here). After the process of cell transfor-
mation, a fraction of cells was loosely attached to the
dishes or even completely detached. The remaining
cells had lost their mutual attachments, and cyto-
plasm retraction with eosinophilia and shrunken
nuclei were also observed, indicating the irreversible
cell injuries. There was no specific difference from
investigations using the light microscope, with
respect to the cell morphology and foci number
between cells exposed to NPs and the negative con-
trol group. However, the morphology of positive
control was apparently different from that of the
NPs and negative control. The strong transformed
cells were unlikely to be taken a picture because of
their pyramidal morphology. Nevertheless at the
weak sites of transformant, NITH/3T3 cells for NPs
and positive control showed respectively lilac
[Fig. 5(a)] and deep purple [Fig. 5(b)], indicating the
positive control groups were more basophilic.
In vitro hemolysis
Red blood cells (RBCs) are the first cells that come
into contact with intravenous administration. In vitro
erythrocyte-induced hemolysis is considered to be a
TABLE I






















DMSO (control) None None 100 0 0 0.30 6 0.48 3
Au–Au2S NPs 300 None 60 0.80 6 0.78 6 1.00 6 0.67 8
Au–Au2S NPs 30 None 81 0.40 6 0.70 3 0.60 6 0.70 5
Cisplatin-loaded NPs 125 120 69.5 0.70 6 0.67 5 0.90 6 0.57 7
Cisplatin-loaded NPs 12.5 12 100 0.50 6 0.52 4 0.60 6 0.52 7
MCA (þcontrol) None None 91 0.50 6 0.52 3 3.50 6 1.08* 10
*denotes significant difference from negative control (p < 0.05).
TABLE II






















DMSO (control) None None 100 0 0 0.30 6 0.48 2
Au–Au2S NPs 200 None 55 0.70 6 0.67 6 1.10 6 0.74 8
Au–Au2S NPs 20 None 88 0.50 6 0.52 5 0.60 6 0.70 5
Cisplatin-loaded NPs 80 77.5 71.5 0.80 6 0.79 6 1.50 6 0.85 9
Cisplatin-loaded NPs 8 7.7 95 0.60 6 0.52 6 0.80 6 0.63 7
MCA (þcontrol) None None 91.4 0.50 6 0.52 3 3.50 6 1.08* 10
*denotes significant difference from negative control (p < 0.05).
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simple and reliable measure for estimating blood
compatibility of materials.34 The interactions of vari-
ous NPs with the negatively charged RBCs have been
studied by hemolysis experiments,35–37 and the
behavior of the NPs in vivo can be predicted by inves-
tigating the degree of hemolysis in vitro. In this paper,
the hemolysis ratio represents the extent of blood
cells broken by Au–Au2S NPs in contact with blood.
The release of hemoglobin was used to quantify the
membrane-damaging properties of the Au–Au2S
NPs. As 100% and 0% values we used deionized
water and normal saline treated erythrocytes, respec-
tively. It is acceptable that hemolysis ratio (HR%) of
biomaterials, which was required for medical applica-
tions, must be below 5%.38 The dose effects of Au–
Au2S NPs and cisplatin-loaded Au–Au2S NPs on he-
molysis were shown in Figure 6. Increasing the mass
of Au–Au2S NPs or cisplatin-loaded Au–Au2S NPs
resulted in enhanced hemolysis ratio. For example,
by adding the mass of Au–Au2S NPs from 1 lg/mL
to 100 lg/mL, the HR% increased from 0.22% to
2.04%. On the other hand, increasing the mass of cis-
platin-loaded Au–Au2S NPs from 1 lg/mL to 80 lg/
mL, the HR% increased from 2.14% to 4.83%. 5.32%
hemolysis took place when cisplatin-loaded Au–Au2S
NPs reached 100 lg/mL. There was a statistically sig-
nificant difference between the bare Au–Au2S NPs
and cisplatin-loaded Au–Au2S NPs. Despite this find-
ing, it is unlikely that cisplatin is responsible for the
onset of hemolysis because only a little amount (1.2%)
of cisplatin was released when performed in room
temperature,18 and the hemolysis ratio of cisplatin (1–
100 lg/mL) alone were below 1%, which varied from
0.017% to 0.77%. The known hemolytic effects may
arise from the change in permeability (colloid osmotic
lysis or hemoglobin loss), phagocytosis of damaged
cells, or fragmentation of the membrane.39 Since no
change for pH value or ionic concentration was
observed through our experiments, the NPs might
play an important role for hemolytic activity. We
hypothesized that the more positive charged cisplatin-
loaded Au–Au2S NPs (*20 mV) is easier than the
bare Au–Au2S NPs (*7 mV) to affect the membrane
of RBC until it breakdown, leading to the subsequent
release of some hemoglobin-like surface-active chemi-
cals.40 This suppose, of course, needed to be further
examined. Nevertheless, it could be concluded that
cisplatin-loaded Au–Au2S NPs with concentration
below 80 lg/mL cause negligible hemolysis (<5%),
and could be used for cancer therapy.
SUMMARY
In the present study, NIR-sensitive Au–Au2S NPs
were synthesized by the reduction of tetrachloroauric
acid (HAuCl4) using sodium sulfide (Na2S), and cis-
Figure 5. Morphology of transformed cells observed
under light microscopy. (a) cisplatin-loaded Au–Au2S
NPs-treated NIH/3T3 cells; (b) positive control-treated
NIH/3T3 cells. [Color figure can be viewed in the online
issue, which is available at www.interscience.wiley.com.]
Figure 6. Hemolysis effects as a function of the concen-
tration of Au–Au2S NPs (NPs) and cisplatin-loaded Au–
Au2S NPs (Pt-NPs). Bars represent the corresponding
standard deviations (n ¼ 3).
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platin was loaded onto NIR-sensitive Au–Au2S NPs
via a MUA layer. TEM images indicated that both
Au–Au2S NPs and cisplatin-loaded Au–Au2S NPs
could be observed associated with the plasma mem-
brane or in small vesicles of the cells. Our in vitro
short- and long-term data provided preliminary evi-
dence suggesting that cisplatin-loaded Au–Au2S NPs
were nontoxic below the maximum recommended
dosage. Therefore, the demonstrated biocompatibility
offers the potentials of cisplatin-loaded Au–Au2S NPs
with NIR sensitivity for cancer therapy.
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